Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Friday, August 14, 2026, evening edition, written with the U.S. session in its final stretch. Thursday’s record did not carry into Friday, and two data points did most of the work. July retail sales fell 0.6% from June, the sharpest monthly drop since May 2025 and the opposite of the small rise the consensus looked for. The preliminary August reading of University of Michigan consumer sentiment came in at 51.0 against 55.2 in July, ending two consecutive months of improvement, with the cost of living named as the dominant concern. The tape gave back a fraction of the week rather than reversing it: the broad index and the Nasdaq-100 fund are both down less than half a per cent, small caps are up, and Applied Materials is the worst large-cap performer of the session after beating and raising on Thursday night. Biotech, the one sector lower on Thursday, is the one holding its ground today, carried by two moves of more than forty per cent. All marks below are intraday, taken at 2:05 p.m. New York time, and are not closing prices.

Friday’s tape, with the bell still to come
  • $SPY — The S&P 500 tracker was at $775.99, down 0.24% from Thursday’s $777.88, giving back a slice of the record.Equities
  • $QQQ — The Nasdaq-100 fund was at $729.64, down 0.33%, ending a four-session run of leading the market.Equities
  • $DIA — The Dow tracker was at $536.82, down 0.20%. The blue-chip index has now gone six sessions without a direction.Equities
  • $IWM — Small caps were the exception on the upside at $304.38, up 0.29%, the only one of the four broad trackers higher.Small caps
  • $SMH — The semiconductor tracker was at $583.90, down 0.89%, the weakest of the sector funds, with Applied Materials doing most of the damage.Semis
  • $XBI — Biotech was flat at $156.81, down 0.03%, after Thursday’s 1.59% fall. $IBB was at $198.01, down 0.47%.Biotech
The morning’s data
  • Retail sales — July receipts fell 0.6% month on month, against June’s 0.2% rise and a consensus that looked for a further increase. It is the steepest monthly decline since May 2025.Macro
  • Michigan sentiment — The preliminary August index printed 51.0 against 55.2 in July, ending two months of improvement. The survey attributes the deterioration to the cost of living rather than to the labour market.Macro
  • The rate debate — Both prints landed on the same side of the September argument as Wednesday’s consumer price index and Thursday’s flat producer prices: a consumer that is spending less and feeling worse.Macro
  • $TLT — The long-bond fund was at $81.92, down 0.82%, a move in the opposite direction to what the demand data alone would suggest. The bond market did not take the weak consumer as the settled story.Rates
Biotech and healthcare
  • $CAPR — Capricor was at $6.42, up 52.49% on 57.7 million shares, the largest move in the sector. The Lancet published the HOPE-3 phase 3 data for deramiocel in Duchenne muscular dystrophy, and Cantor Fitzgerald upgraded the stock. The PDUFA date is August 22, 2026, and the advisory committee voted 9 to 3 against substantial evidence of effectiveness on July 29.Biotech
  • $ETON — Eton Pharmaceuticals was at $57.86, up 41.82%, after second-quarter revenue of $37.6 million, roughly double a year earlier, and full-year 2026 guidance lifted to more than $145 million from more than $120 million.Pharma
  • $HTFL — HeartFlow was at $42.20, up 36.08% on 7.6 million shares, the third of the day’s outsized healthcare moves.Medtech
  • $INO — Inovio was at $1.06, up 17.76%, a second consecutive double-digit session after its second-quarter results.Biotech
  • $HUMA — Humacyte was at $0.61, up 11.60% on 27.5 million shares, rebounding after two heavy sessions.Biotech
  • $VERA — Vera Therapeutics was at $31.71, up 9.77%, among the larger mid-cap gainers in the sector.Biotech
  • $OTLK — Outlook Therapeutics was at $0.76, down 14.33% on 75.8 million shares, a second heavy session around the closing of its offering.Biotech
  • $ZNTL — Zentalis was at $3.52, down 15.30%, and $SANA at $3.40, down 7.22%, the two largest declines among the mid-cap names.Biotech
Applied Materials, and the memory trade that keeps going
  • $AMAT — The shares were at $504.70, down 5.58%, the worst large-cap performance of the session. Fiscal third-quarter revenue was $9.12 billion against guidance near $8.95 billion, adjusted earnings were $3.50 per share against about $3.36 guided, and fourth-quarter revenue was guided to $10.25 billion plus or minus $500 million against a consensus nearer $9.5 billion.Semi equipment
  • The reading — A beat and a raise of that size followed by a fall of more than five per cent is the same pattern that took eight per cent out of Cisco on Thursday: the numbers are being measured against the run into them, not against the estimates.Semi equipment
  • $SNDK — Sandisk was at $1,633.15, up 6.87%, a second consecutive double-digit-scale advance and the clearest sign that memory pricing is still the engine of this leg.Semis
  • $MU — Micron was at $963.55, up 1.44%, moving with the same story. $CSCO was at $112.06, down 1.25%, extending Thursday’s fall.Semis
Drone tariffs, defense and space
  • The measure — The Section 232 proclamation signed on August 13 puts a 100% duty on imported drones from September 3, with a 25% component tier deferred to February 9, 2027. The 100% component lines are restricted to aircraft above 25 kg and carve out sales to the Department of War.Trade
  • $UMAC — Unusual Machines was at $33.23, up 21.99% on 12.7 million shares, the largest beneficiary of the reading that the measure protects domestic assemblers.Drones
  • $LPTH — LightPath was at $15.11, up 15.21%. Infrared optics, lenses and thermal sensors do not appear as tariff lines in the annexes, so the payload sold separately is not caught by the finished-aircraft trigger.Optics
  • Drone names — $RCAT was at $10.93, up 6.79%, $DPRO at $4.84, up 4.65%, $ONDS at $9.11, up 2.30%, $KTOS at $64.21, up 2.26%, and $AVAV at $192.23, up 1.48%.Drones
  • $LUNR — Intuitive Machines was at $19.26, up 9.68% on 14.6 million shares, after being selected by L3Harris to supply 18 IM-1300 spacecraft platforms for a Space Development Agency missile-defense mission, with contracted backlog at a record $1.8 billion.Space
  • $RKLB — Rocket Lab was flat at $80.13, up 0.04%, and $SPCX was at $140.01, down 0.91%, holding above its $135 June listing price.Space
  • Nuclear — $SMR was at $9.35, down 5.10%, and $OKLO at $44.94, down 3.26%, both giving ground while the uranium miners held: $CCJ at $97.76 and $UEC at $11.26, both effectively unchanged.Energy
Commodities, the dollar and the offerings of the day
  • Gold and crude — $GLD was at $401.89, up 0.73%, recovering Thursday’s retreat, and $USO at $126.21, up 0.94%, after two sessions of decline. $UUP was at $28.13, down 0.18%, effectively flat for a second day.Commodities
  • $MVIS — MicroVision was at $2.22, down 41.02%, after pricing 6,800,000 units at $2.50 for gross proceeds of about $17.0 million. Each unit carries one share and one five-year warrant exercisable at $2.50, and the offering is expected to close around August 17.Financing
  • $OTLK — The definitive prospectus supplement put net proceeds at $51.1 million against $55.0 million gross. The underwriters exercised their option on the warrants only, taking the warrant count to 63,888,889 and total overhang to 121,480,867 shares.Financing
  • $OTLK — The fiscal third quarter ended June 30 showed net revenue of $9 thousand, an operating loss of $10.8 million, a net loss of $20.3 million and cash of $11.2 million, six days before the U.S. approval of Lytenava.Financing
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 8 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open. October and later events are excluded from this widget.

35Active
18FDA / Reg
17Data / Filing
Aug 14Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEOngoingFDA reviewFirst-cycle review complete; vial certification remains

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the file is no longer accurately described as having “no outcome.” On August 7, NRx reported that FDA completed the first-cycle review of the ANDA for preservative-free intravenous ketamine with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related matters. One major deficiency remains tied to the container-closure system: manufacturer certification concerning the luer-lock vial tip. Following an August 6 clarification meeting, FDA requested signed documentation and, according to the company, intends to review it in the shortest applicable cycle. No new exact action date has been disclosed.

$REGNgaretosmabAugBLAPriority Review in adult FOP

Regeneron. The BLA for garetosmab in adults with fibrodysplasia ossificans progressiva remains under Priority Review. Regeneron continues to guide to an FDA decision in August 2026 without disclosing an exact day.

$LNTHTAUKLARIFYAug 14ApprovedFDA approves the tau PET imaging agent in Alzheimer’s disease

Lantheus. FDA approved TAUKLARIFY (florquinitau F 18 injection), previously known as MK-6240, on August 14, 2026, the day after the PDUFA target date. The agent is indicated for PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer’s disease, to identify patients with tau neurofibrillary tangle pathology. Safety and effectiveness have not been established for non-Alzheimer’s tauopathies. Approval is supported by two blinded-read studies covering more than 500 subjects: positive percent agreement ran from 80% to 88% and negative percent agreement from 98% to 99% in Study 1 (n=279), and from 68% to 82% and 93% to 99% in Study 2 (n=338). Lantheus intends to keep supporting Alzheimer’s therapeutic programs through its Pharma Solutions business while assessing the path toward broader commercial availability, so launch timing, coding and reimbursement remain open rather than settled.

$BMYiberdomide comboAug 17NDARRMM · iberdomide + daratumumab/dexamethasone

Bristol Myers Squibb. Priority Review PDUFA for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. The application also has Breakthrough Therapy Designation for this indication.

$CAPRderamiocelAug 22Extreme riskPDUFA after 9–3 negative AdCom efficacy vote

Capricor. The resubmitted BLA for deramiocel in Duchenne muscular dystrophy-associated cardiomyopathy remains formally under review with an August 22 action date. On July 29, the advisory committee voted 9–3 that the available evidence did not provide the required substantial evidence of effectiveness. FDA is not bound by the vote, but the negative panel result, disputes over endpoint interpretation and the prior CRL make this an exceptionally high-risk regulatory event.

$RAREDTX401Aug 23BLAGene therapy for GSDIa

Ultragenyx. Priority Review PDUFA for the DTX401 (pariglasgene brecaparvovec) BLA in glycogen storage disease type Ia. The company reaffirmed the August 23 date in its August 4 update.

$JAZZZiihera comboAug 25sBLAFirst-line HER2-positive GEA

Jazz Pharmaceuticals. Priority Review PDUFA for the Ziihera (zanidatamab-hrii) sBLA in combination with chemotherapy, with or without tislelizumab, for first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDAOnce-daily oral HIV regimen

Gilead. Priority Review PDUFA for the bictegravir 75 mg/lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV. This is a strategic lifecycle catalyst for the HIV franchise.

$PTGXrusfertideAugNDAPriority Review in polycythemia vera

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review with a publicly disclosed August 2026 PDUFA goal month. Because no independently verifiable exact day has been published, this board correctly shows the month only.

$TLXPixclaraSep 11NDAPET imaging in glioma

Telix Pharmaceuticals. PDUFA target date for the resubmitted Pixclara (TLX101-Px) NDA. The PET imaging agent is intended to help characterize suspected recurrent or progressive glioma versus treatment-related changes.

$RAREUX111Sep 19BLAGene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A. The company reaffirmed September 19 in its August 4 update; the application seeks accelerated approval.

$MRKWINREVAIRSep 21sBLAPAH · HYPERION-based label update

Merck. PDUFA for an sBLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. Merck reaffirmed the September 21 date with its second-quarter results.

$IONSzilganersenSep 22NDAAlexander disease

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. It remains one of September’s most closely watched rare-disease regulatory catalysts.

$GRALGalleriSep 23FDA panelAdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel will meet on September 23 to discuss and vote on the Galleri premarket approval application. Galleri is a blood-based multi-cancer early detection test proposed for screening adults aged 50 and older. This is not a drug PDUFA; it is a device and diagnostics regulatory catalyst that is nevertheless material to the stock.

$MIRMzilurgisertibSep 26NDAFOP · patients aged 12 and older

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 years and older. Mirum holds exclusive worldwide rights under license from Incyte.

$BFRIAmeluz PDTSep 28sNDAExpansion into superficial BCC

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. FDA completed its filing review without identifying filing deficiencies and assigned September 28 as the target action date.

$SRRKapitegromabSep 30BLASMA · review continues with second fill-finish site

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 7, the company said that, in coordination with FDA, Catalent Indiana is being removed from the BLA and review is continuing using the second fill-finish facility; the related data package is under review. CMC and manufacturing risk therefore remain central, while the company continues to state that the action date is unchanged.

$ROIVbrepocitinibQ3NDADermatomyositis · Priority Review

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The company has disclosed a PDUFA target action date in the third quarter of 2026 and, if approved, has pointed to a possible U.S. launch around the end of September. No exact PDUFA day has been made public.

$QUREAMT-130Q3BLAAccelerated-approval BLA filing in Huntington’s disease

uniQure. The company is preparing an AMT-130 BLA in Huntington’s disease after alignment with FDA on a pathway that may use comparison with an external control as the primary basis of the application. The submission remains a Q3 2026 catalyst; it is not a PDUFA, and FDA filing acceptance would be the next formal step.

$SLNdivesiranAugDataSANRECO Phase 2 in polycythemia vera

Silence Therapeutics. Phase 2 SANRECO topline data for divesiran in polycythemia vera are expected in August. The readout also provides a particularly relevant class comparison with rusfertide from $PTGX / Takeda.

$TENXTNX-103AugPhase 3Registrational LEVEL study · PH-HFpEF

Tenax Therapeutics. Topline results from the registrational Phase 3 LEVEL study of TNX-103, oral levosimendan, in pulmonary hypertension associated with heart failure with preserved ejection fraction are expected in August 2026. The results are also scheduled for a Late-Breaking Clinical Science presentation at ESC on August 29.

$EYPTDURAVYU / LUGANOAugPhase 3Pivotal wet AMD topline

EyePoint. Phase 3 LUGANO topline data for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration are expected in August 2026. LUGANO is the first of two fully enrolled global pivotal trials comparing six-month DURAVYU dosing with on-label aflibercept; LUCIA is expected to read out in the fourth quarter. Key variables include visual-acuity noninferiority, supplemental anti-VEGF use, anatomy and ocular safety.

$IMMXNXC-201Late SepDataNEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026. The program is designed as BLA-enabling/registrational, and subsequent follow-up is expected to contribute to the regulatory path.

$KPTIselinexor comboAugsNDASelinexor + ruxolitinib filing in myelofibrosis

Karyopharm. The former XPORT-EC-042 endometrial-cancer catalyst is resolved: on July 30, the study did not meet its primary progression-free-survival endpoint. The active event is now the sNDA the company plans to submit in August for selinexor combined with ruxolitinib in myelofibrosis, with a request for Priority Review.

$KODDAYBREAKSepPhase 3Wet AMD · Zenkuda and KSI-501

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel against aflibercept.

$ALMSenvudeucitinibQ3DataLUMUS Phase 2b in SLE

Alumis. Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter. For an autoimmune readout, the market will assess not only statistical significance but also dose consistency, clinical endpoints and the safety profile.

$IVVDVYD2311Q3DataDECLARATION pivotal study

Invivyd. Topline data from the pivotal Phase 3 DECLARATION study of VYD2311 are expected in the third quarter of 2026. The timing remains company guidance rather than a calendar-specific date.

$AMLXavexitideLate Aug / early SepPhase 3Pivotal LUCIDITY study in PBH

Amylyx. Topline results from the pivotal Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia are now expected in late August or early September 2026. The last participant has completed the final visit in the double-blind treatment period.

$PHVSdeucrictibant XRQ3Phase 3CHAPTER-3 · HAE prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis remain expected in the third quarter of 2026. This is one of the quarter’s most important registrational HAE readouts.

$SYRESPY003SepDataSKYLINE Phase 2 in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study in ulcerative colitis are expected in September 2026, according to the company’s August 4 update.

$VERATRUTAKNA / ataciceptQ3eGFRORIGIN 3 confirmatory follow-up

Vera Therapeutics. The ORIGIN 3 eGFR analysis is expected in the third quarter following accelerated approval of atacicept. This is not another approval decision; its significance lies in the durability of the renal effect and the read-through for the confirmatory pathway.

$XENEazetukalnerQ3NDAFocal-onset seizure filing

Xenon. The azetukalner NDA submission in focal-onset seizures remains on track for the third quarter. Filing confirmation would begin FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIOinfigratinibQ3NDAAchondroplasia filing

BridgeBio. The company intends to submit the infigratinib NDA in achondroplasia in the third quarter. The immediate catalyst is the submission; FDA acceptance and any PDUFA date would follow.

$CLNNCNM-Au8Q3NDAAccelerated pathway in ALS

Clene. The company continues to target a third-quarter NDA submission for CNM-Au8 in amyotrophic lateral sclerosis through an accelerated-approval pathway. Regulatory risk remains high: a planned submission is not the same as FDA filing acceptance or approval.

$MLTXsonelokimabLate SepBLAHidradenitis suppurativa filing

MoonLake. The sonelokimab BLA submission in hidradenitis suppurativa is expected around the end of September 2026. FDA filing acceptance would create the next formal regulatory event.

Most attention-worthy watchlist

$NRXP$CAPR$RARE$PTGX$IONS$GRAL$MIRM$SRRK$TENX$EYPT$AMLX$PHVS$QURE$IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown. $LNTH is the single resolved event kept for this update cycle, because FDA approved TAUKLARIFY on August 14, 2026, the day after its PDUFA target date. $NRXP remains because first-cycle review of the KETAFREE ANDA ended with a residual container-closure certification request and no new exact action date. $SVRA has been removed because FDA extended the MOLBREEVI PDUFA date to November 22, 2026, outside this board. Resolved events for $REPL, $MRNA, $BIIB and $GSK/zidesamtinib have been removed, as have $MPLT’s completed ZEPHYR readout and the former Q3 $OCGN items now guided to 2027. For $KPTI, the completed endometrial-cancer readout has been replaced by the planned August myelofibrosis sNDA. The September 23 $GRAL/Galleri panel and the August $TENX LEVEL and $EYPT LUGANO readouts are included. Month-only and quarter-only windows reflect disclosed company guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events.Full catalyst calendarFDASEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.